Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of telisotuzumab adizutecan combinations in metastatic colorectal cancer
MOH_2025-02-16_013919Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of telisotuzumab adizutecan in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (8 arms), sponsored by AbbVie Inc. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on MOH_2025-02-16_013919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-02-16_013919.